c-FOS is an integral component of the IKZF1 transactivator complex and mediates lenalidomide resistance in multiple myeloma.
Naoki OsadaJiro KikuchiHidekatsu IhaHiroshi YasuiSho IkedaNaoto TakahashiYusuke FurukawaPublished in: Clinical and translational medicine (2023)
C-FOS determines lenalidomide sensitivity and mediates drug resistance in MM cells as a co-factor of IKZF1 and thus, could be a novel therapeutic target for further improvement of the prognosis of MM patients.
Keyphrases
- multiple myeloma
- newly diagnosed
- end stage renal disease
- acute lymphoblastic leukemia
- induced apoptosis
- ejection fraction
- chronic kidney disease
- stem cell transplantation
- prognostic factors
- cell cycle arrest
- peritoneal dialysis
- patient reported outcomes
- signaling pathway
- endoplasmic reticulum stress
- patient reported
- chronic lymphocytic leukemia